Brief: BeyondSpring Reports Exclusive Agreement with Jiangsu Hengrui Pharma for Plinabulin in Greater China
26/08/2021 12:13
Aug 26 (Reuters) - Beyondspring Inc BYSI.O :
* BEYONDSPRING ANNOUNCES EXCLUSIVE COMMERCIALIZATION AND
CO-DEVELOPMENT AGREEMENT WITH JIANGSU HENGRUI PHARMACEUTICALS
FOR PLINABULIN IN GREATER CHINA
* BEYONDSPRING INC - WANCHUNBULIN TO RECEIVE UP TO 1.3B RMB
(EST.
$200M USD) IN MILESTONE PAYMENTS
* BEYONDSPRING INC - HENGRUI TO PAY FOR 100% OF
COMMERCIALIZATION
COSTS FOR PLINABULIN IN TERRITORY AND RECEIVE A PRE-DETERMINED
PERCENTAGE OF NET SALES
* BEYONDSPRING INC - HENGRUI TO MAKE 100M RMB EQUITY
INVESTMENT IN
WANCHUNBULIN AT A PRE-MONEY VALUATION OF 3.6B RMB
* BEYONDSPRING INC - WANCHUNBULIN TO BOOK REVENUE AND TO PAY
FOR
100% COST OF GOODS SOLD
Source text for Eikon: ID:nGNXFg6L8
Further company coverage: BYSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beyondspring
See all newsBrief: Beyondspring Inc Entered Into Open Market Sale Agreement Under Which Co May Offer And Sell Up To 9.2 Million Ordinary Shares
Brief: Beyondspring Announces FDA Fast Track Designation For Plinabulin In Post-Ici Non-Squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis
NASDAQ RESUMED AT 12:26 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:21 PM
Brief: Beyondspring Announces Leadership Transition To Deliver Focused Execution On Its Confirmatory Dublin-4 Program And Long-Term Value